Ozempic & Eating Disorders: Risks of GLP-1s for Unhealthy Weight Loss

The rapid rise in popularity of GLP-1 receptor agonists – medications like Ozempic and Wegovy initially developed to manage type 2 diabetes – has brought with it a growing concern: the potential for exacerbating or even triggering eating disorders. While these drugs offer significant benefits for some, their effects on appetite and weight are mirroring patterns seen in conditions like anorexia and bulimia, creating a complex challenge for both patients and healthcare providers. The very mechanisms that make these medications effective for weight loss can, for vulnerable individuals, reinforce disordered thoughts and behaviors, blurring the lines between therapeutic use and relapse.

The overlap between the intended effects of GLP-1s and the hallmarks of eating disorders is proving particularly difficult to navigate. As Dr. Brad Smith, chief medical officer for The Emily Program, explains, it can be challenging to determine whether a patient is responding to the medication as expected or is experiencing a return of disordered eating patterns. The Emily Program, a national network of eating disorder treatment centers, is seeing an increasing number of cases where GLP-1s appear to be validating and reinforcing unhealthy relationships with food and body image, rather than prompting intervention.

A Growing Trend: Misuse and Relapse

Experts are observing two distinct, yet related, trends. Ruth Elliott, LICSW, director of clinical services at Multi-Service Eating Disorders Association in Massachusetts, notes that her practice is witnessing both instances of GLP-1 misuse – where the drugs are used for weight loss outside of medical necessity – and active relapse in individuals with a history of eating disorders. This isn’t entirely unexpected, as weight loss medications have historically been linked to the re-emergence of disordered eating behaviors. However, GLP-1s appear to be having a “much higher impact” than previous substances, according to Smith.

A significant contributing factor is the lack of comprehensive patient screening. The ease of access to GLP-1s, particularly through telehealth companies that don’t require in-person evaluations, raises concerns. These companies may rely on self-reported information regarding weight and eating disorder history, potentially overlooking crucial warning signs. Even when patients seek prescriptions through traditional medical channels, thorough mental health and eating disorder screenings are often lacking.

Beyond Weight Loss: The Complexities of GLP-1s

It’s crucial to understand that GLP-1s are not approved treatments for eating disorders. Sam DeCaro, PsyD, director of clinical outreach and education for the Renfrew Center, emphasizes that weight loss itself is not a treatment or cure for the complex psychological, social, and cultural roots of these illnesses. In fact, the medications can actively reinforce disordered thinking. For individuals already struggling with an eating disorder, the promise of weight loss can be particularly appealing, even if they haven’t reached a full state of recovery.

The risk is further amplified for those with co-occurring mental health conditions, which are common among individuals with eating disorders. Research suggests that GLP-1 users with pre-existing conditions like depression, anxiety, and bipolar disorder are 2.4 times more likely to be diagnosed with an eating disorder compared to those without a mental health history. As reported in Slate, this highlights the importance of a holistic approach to patient evaluation and treatment.

The Physiological Impact: A Delicate Balance

GLP-1s operate by mimicking the effects of glucagon-like peptide-1, a hormone naturally released by the intestines after a meal. This hormone signals to the brain that you’re full, slowing down digestion and reducing appetite. While this mechanism can be beneficial for managing weight, it also interferes with the body’s natural hunger and satiety cues. Chronically overstimulating this signaling pathway, as occurs with pharmacological doses of GLP-1s, can disrupt normal physiological function, potentially leading to adverse effects.

Between 40 and 70 percent of patients on these drugs report gastrointestinal issues like acid reflux, chronic diarrhea, and constipation. More concerningly, studies indicate a nearly fourfold increased risk of gastroparesis – a condition characterized by delayed stomach emptying, causing bloating and pain – and a ninefold increased risk of pancreatitis compared to individuals on other weight-loss medications. These side effects, while not directly related to eating disorders, can further complicate the relationship with food and body image.

The Emergence of “Agonorexia”

A new term, “agonorexia,” has emerged to describe the phenomenon of individuals using GLP-1s not for their intended medical purpose, but to pursue extreme thinness, often coupled with restrictive eating behaviors. The New York Post has reported on this trend, highlighting how the drugs can fuel a dangerous obsession with food and body image. What we have is particularly alarming because it can affect individuals who have never previously struggled with an eating disorder.

What Comes Next: Enhanced Screening and Responsible Prescribing

Addressing this growing concern requires a multi-faceted approach. Enhanced patient screening is paramount, with a focus on identifying individuals with a history of eating disorders or co-occurring mental health conditions. Healthcare providers require to be adequately trained to recognize the warning signs of disordered eating and to conduct thorough assessments before prescribing GLP-1s. Telehealth companies should implement stricter protocols to ensure appropriate patient evaluation.

it’s essential to emphasize that GLP-1s are not a quick fix for weight loss and should not be used as a substitute for comprehensive lifestyle changes, including a balanced diet and regular exercise. Open and honest communication between patients and healthcare providers is crucial, with a focus on addressing the underlying psychological and emotional factors that contribute to disordered eating. Continued research is needed to better understand the long-term effects of GLP-1s on mental health and eating behaviors, and to develop effective strategies for preventing and treating GLP-1-related eating disorders.

responsible prescribing and a heightened awareness of the potential risks are essential to ensure that these medications are used safely and effectively, without inadvertently exacerbating or triggering a life-threatening illness.